The Next Leap for India’s Pharma Sector

This editorial is based on “India is the pharmacy of the world. But we are losing the drug development race” which was published in The Indian Express on 30/03/2026. The article brings into picture the paradox of India’s dominance in generic drug manufacturing alongside its weak innovation in new drug development due to regulatory delays.

It highlights that without urgent reforms, India risks missing the AI-driven transformation in high-value pharmaceutical innovation.

India is the world's largest manufacturer of generic medicines, yet it develops almost no new drugs of its own. The core bottleneck is a slow clinical trial approval system, where a single overloaded regulator can take years to greenlight trials that China clears in days. With AI now compressing drug development timelines from years to months, this regulatory lag is costing India its window to lead in next-generation medicine. India urgently needs to reform both its clinical trial framework and its broader pharmaceutical ecosystem, so as not to remain a low-margin generic manufacturer in a world rapidly moving towards high-value, AI-driven drug innovation.

What are the Major Recent Developments Shaping India’s Pharmaceutical Sector?

• Upstream Self-Reliance: India is aggressively reducing its chronic dependency on single-source imports for critical Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) to secure its supply chains. This strategic shift moves the sector from a vulnerable "formulator-only" model to a vertically integrated manufacturing powerhouse.
  • For instance, the PLI scheme for bulk drugs has exceeded expectations, attracting ₹4,814 crore investment (against ₹4,329 crore committed) in greenfield projects by Dec 2025.
  • It has created 56,800 Metric Tonnes Per Annum capacity for critical APIs/KSMs, generating ₹2,720 crore in sales, including ₹528 crore in exports.
• Breakthrough in Indigenous Antimicrobials: India has transitioned from a generic manufacturer to an innovator with the development of Nafithromycin, the country’s first indigenously conceptualized and clinically validated antibiotic. 
  • This discovery is a strategic response to the global Antimicrobial Resistance (AMR) crisis, proving that Indian R&D can produce "First-in-Class" molecules for life-threatening respiratory infections.

• Transition to "Pharma 4.0": The industry is pivoting toward "Digital Biology" and AI-driven drug discovery to compress the traditional 10-year development cycle and enhance manufacturing precision. 

  • This digital leap is essential for Indian firms to compete in the complex biologics and "Digital Therapeutics" (DTx) markets globally.

  • In 2026, AI-powered pharmacovigilance and "Digital Twins" for clinical trial simulations have become mainstream, with the clinical trials market in India is expected to reach a projected revenue of USD 2954.1 million by 2033.
• Mega Bulk Drug & Medical Device Parks: The government is decentralizing production and creating "plug-and-play" infrastructure to lower the cost of production through common effluent treatment and logistics facilities.
  • These parks represent a shift toward "Clusters of Excellence" that allow MSMEs to scale without prohibitive capital expenditure on infrastructure.
  • For instance, 3 Bulk Drug Parks were approved in FY 2022-23 in the States of Andhra Pradesh, Gujarat and Himachal Pradesh. Financial assistance from the Central Government is provided for creation of Common Infrastructure Facilities (CIF).
• Quality Harmonization- The Revised Schedule M Mandate: There is a rigorous enforcement of international quality standards (GMP) to repair the global reputation of Indian exports following recent international regulatory scrutiny. 
  • In 2024, India revised Schedule M under the Drugs and Cosmetics Rules to strengthen quality standards by expanding GMP norms to include requirements for premises, plant, and equipment.
  • Adopting these "Global Standard" benchmarks is no longer optional but a survival prerequisite for Indian firms eyeing the US and EU markets.
  • Also, India has the largest number of USFDA-compliant plants outside the US and over 2,000 WHO-GMP approved facilities, exporting to 150+ countries
• High-Value Diversification: Indian pharma is moving beyond simple chemical generics into the high-margin "New Biological Entities" (NBEs) and complex biosimilars space to capture the next wave of global patent expiries. 
  • This transition is critical as the domestic biosimilar market is expanding rapidly, reflecting a sophisticated shift in scientific capability.
  • For instance, the Biosimilar market in India was valued at approximately Rs. 437 crore in 2024 and is estimated to grow around Rs. 1,649 crore by 2034 with a compounded annual growth rate (CAGR) of 14.2%.
    • Major players like Cipla and Biocon are increasingly utilizing the PRIP (Promotion of Research and Innovation in Pharma) scheme to fund breakthroughs in CAR-T cell and mRNA therapies
• The Transition to High-End Medical Devices: India is shifting from being a net importer of medical technology to a hub for high-end diagnostic and surgical equipment through dedicated industrial parks and incentive schemes. 

  • This transformation aims to reduce the current 70-80% import dependency for sophisticated equipment like MRI and CT scanners.

  • The PLI Scheme for medical devices, with an outlay of ₹3,420 crore, is promoting domestic manufacturing in high-end segments such as MRI, CT, and radiotherapy equipment. 
    • By September 2025, 22 projects had operationalized 55 products, generating ₹12,344 crore in sales, including ₹5,869 crore in exports.
• National Mission for Biologics and Biosimilars: The government has introduced a dedicated "Biopharma SHAKTI" initiative in Union Budget 2026–27 to catalyze the end-to-end ecosystem for biologics, which are more complex and high-value than traditional chemical drugs.

  • This strategic move targets a 5% share of the global biopharmaceutical market, positioning India as a "Pharmacy to the World" for next-gen treatments as well.

  • The government is also focusing on expansion and strengthening of the Biopharma-focused network through the establishment of 3 new National Institutes of Pharmaceutical Education and Research (NIPERs) and the upgradation of seven existing NIPERs.
• Green Pharma- ESG Integration and Sustainable Chemistry: Indian pharmaceutical giants are moving toward "Biopositive" manufacturing by adopting green chemistry, flow chemistry, and renewable energy to meet stringent global Environmental, Social, and Governance (ESG) standards. 

  • This shift is critical for maintaining access to regulated markets in the EU and US, where supply chain sustainability is becoming a non-negotiable trade requirement.

  • Current estimates show that adopting flow chemistry and solvent recovery has allowed leading firms to reduce chemical waste at select pilot facilities.

What are the Key Issues Associated with India's Pharma Sector?

• Quality Perception Crisis- The "Spurious Drug" Stigma: Recurrent global alerts regarding contaminated Indian-made syrups and eye drops have severely dented the "Brand India" reputation, highlighting inconsistent adherence to Good Manufacturing Practices (GMP). 

  • Failure to harmonize quality across MSMEs leads to a fragmented regulatory landscape where substandard products jeopardize international trust and patient safety.

  • For instance, inspections conducted by CDSCO in collaboration with state regulators, covering 905 units, have revealed widespread non-compliance, with 694 regulatory actions taken as of December 2025, highlighting persistent gaps in adherence to GMP standards.
• The Innovation Deficit- R&D Underinvestment: India remains a "Generic Superpower" but an "Innovation Laggard," with the majority of firms focusing on incremental improvements rather than high-risk, high-reward New Chemical Entities (NCEs). 
  • High capital costs and long gestation periods for drug discovery deter private investment, keeping India dependent on Western intellectual property for life-saving specialty drugs.
  • In terms of Research and Development (R&D) intensity, global firms outperformed Indian firms by a factor of 3.0.
    • While the PRIP (Promotion of Research and Innovation in Pharma) scheme offers support, India’s share in the global pharma innovation market remains minimal.
• Persistent Import Vulnerability- The API Chokepoint: Despite the PLI schemes, India still maintains a high dependency on China for specific fermentation-based APIs and high-end Key Starting Materials (KSMs), creating a strategic "Supply Chain Insecurity." 

  • Volatile geopolitical relations and price fluctuations in the global bulk drug market make Indian finished dosages vulnerable to external cost shocks.

  • For instance, India still imports approximately 65-70% of its total API requirements by value from China.
• Regulatory Overlap and Pricing Friction: The industry grapples with a complex, multi-layered regulatory structure involving the CDSCO, National Pharmaceutical Pricing Authority, and State Licensing Authorities, leading to "Compliance Fatigue" and delayed approvals. 

  • Furthermore, the expansion of the National List of Essential Medicines (NLEM) creates a "Margin Squeeze," where rising input costs cannot be passed to consumers due to strict price caps.

  • Average price reduction due to refixation of prices under the NLEM, 2022 was about 17%, often discouraging MSMEs from upgrading to more expensive, modern manufacturing technology.
• Talent Mismatch and Skill Gaps: There is a growing divergence between traditional pharmacy education and the "Industry 4.0" requirements of Biopharma, requiring expertise in bioinformatics, clinical data science, and complex biologics. 
  • The lack of a high-end research workforce prevents Indian firms from transitioning efficiently into the high-value Cell and Gene Therapy (CGT) and mRNA segments.
  • Despite having a large number of pharmacy colleges, India produces a relatively low number of PhDs in specialized fields like computational chemistry, falling short of the talent needed for global-scale innovation.
• The "Silent" Climate Risk: Sustainability and ESG Compliance: The sector is facing an urgent "Decarbonization Crisis" as global buyers, especially in the EU, begin mandating strict Environmental, Social, and Governance (ESG) data from their suppliers. 
  • Indian MSMEs, which form the backbone of the supply chain, often lack the capital to transition from coal-heavy energy to green manufacturing, risking a massive loss in export market share.
  • For instance, Pharmaceutical cleanrooms can consume up to 15 times more energy than commercial building systems, with more than 50% of electricity being consumed by plant HVAC cleanroom systems
• The Digital Divide- Fragmented Data and Cybersecurity: While "Pharma 4.0" is the goal, most Indian firms suffer from "Data Silos" where manufacturing, quality control, and R&D systems do not communicate, leading to documentation errors and FDA warning letters. 
  • Furthermore, the rapid move toward connected OT (Operational Technology) has opened a "Cyber-Vulnerability Gap," making critical manufacturing lines targets for ransomware that can halt life-saving drug production.
• The "Biosimilar Paradox": Transitioning into biosimilars is proving difficult due to "Patent Thickets" dense webs of secondary patents created by innovators to delay competition and the extreme cost of Phase 3 clinical trials.
  • Unlike chemical generics, biosimilars require specialized "Cold-Chain Logistics" and deep scientific trust, making the "Price-Performance Ratio" difficult to maintain for smaller Indian players.
  • Developing a biosimilar costs more than $100 million and takes 5 to 9 years. A conventional generic costs $1 to $2 million and takes roughly 2 years. 

What Measures Should India Adopt to Strengthen and Advance its Pharmaceutical Sector?

• Regulatory Harmonization- Transitioning to "Single-Window" Centralization: India must consolidate its fragmented state-level licensing into a unified federal structure under a "National Pharmaceutical Regulatory Authority" to eliminate jurisdictional overlaps and "Compliance Fatigue." 

  • This "One Nation, One Regulator" model would standardize Good Manufacturing Practices (GMP) across MSMEs, ensuring that quality audits are globally synchronized with WHO-PICS standards. 

  • By digitizing the entire product lifecycle from "Lab-to-Market" via an integrated portal, the sector can drastically reduce the "Approval-to-Launch" lead time for innovative therapeutics.

• R&D Renaissance- Risk-Sharing via "Innovation Bonds" and VGF: To move beyond generic reverse-engineering, the government should introduce "Pharma-specific Innovation Bonds" and Viability Gap Funding (VGF) to de-risk high-gestation New Chemical Entity (NCE) research. 

  • Establishing "Center of Excellence" clusters that facilitate seamless "Industry-Academia-Clinician" synergy will bridge the "Valley of Death" in drug discovery where promising molecules fail due to lack of capital. 

  • A dedicated "Patent Box Tax Regime" with deep concessions for indigenously developed intellectual property would further incentivize local firms to pivot toward high-value "New Biological Entities."

• Supply Chain Fortification: Beyond PLI to "Circular Bio-Manufacturing": Strengthening upstream self-reliance requires a shift toward "Circular Bio-Manufacturing" and green chemistry to neutralize the "China-plus-One" dependency on critical fermentation-based APIs. 

  • Developing "Plug-and-Play" infrastructure in Mega Bulk Drug Parks with common solvent recovery and effluent treatment plants will lower the entry barrier for MSMEs while ensuring environmental sustainability. 

  • By incentivizing "Backward Integration" into Key Starting Materials (KSMs) through tiered production incentives, India can shield its export-oriented model from global geopolitical volatility and price shocks.

• Accelerating"Pharma 4.0" and AI-Bio Integration: The sector must aggressively adopt "Digital Twin" technology and AI-driven predictive modeling to optimize manufacturing yields and compress the duration of complex clinical trials. 

  • Implementing "Blockchain-enabled Traceability" across the end-to-end supply chain is essential to combat the "Counterfeit Menace" and restore global "Brand India" trust in pharmaceutical exports. 

  • Integrating "Real-World Evidence" (RWE) into the regulatory approval process will allow for faster market access for life-saving specialty drugs while maintaining rigorous safety standards through automated pharmacovigilance.

• Human Capital Upskilling- Bridging the "Biopharma-Bioinformatics" Gap: India needs a radical overhaul of its pharmacy curriculum to incorporate "Computational Biology," genomics, and advanced bioprocessing to prepare a workforce for the "Biologics Wave." 

  • Establishing "Industrial Finishing Schools" in partnership with global biotech giants will ensure that graduates possess the "Industry-Ready" skills required for high-end R&D and complex biosimilar production. 

  • By creating "Global Talent Corridors" and offering research fellowships for "Reverse Brain Drain," India can attract world-class scientific leadership to head its emerging Cell and Gene Therapy (CGT) sectors.

• Strategic Market Diversification: India should pivot toward "Orphan Drug" development and treatments for "Neglected Tropical Diseases" (NTDs) to secure a dominant first-mover advantage in untapped global south markets. 

  • Providing "Fast-Track Market Exclusivity" for indigenous drugs targeting domestic healthcare challenges like AMR or metabolic disorders will create a sustainable "Innovation-to-Revenue" loop. 

  • This "Mission-Mode" approach, supported by government-backed "Purchase Guarantees" for novel indigenous molecules, will catalyze a self-sustaining ecosystem for high-risk pharmaceutical entrepreneurship.

• ESG-Led Global Integration: Adopting a "Carbon-Neutral Manufacturing" mandate is no longer a choice but a prerequisite for maintaining access to highly regulated EU and US markets under emerging ESG disclosure norms. 

  • Transitioning to renewable energy-powered "Greenfield Facilities" and adopting "Flow Chemistry" will minimize hazardous waste and significantly reduce the environmental footprint of API synthesis. 

  • By positioning India as a "Sustainably Sourced" pharmaceutical hub, the industry can command a "Green Premium" and differentiate itself from competitors relying on legacy, high-emission production methods.

Conclusion: 

India stands at a critical inflection point—poised between its legacy as a global generic leader and its aspiration to become an innovation-driven pharmaceutical powerhouse. Bridging regulatory gaps, boosting R&D, and embracing AI-led “Pharma 4.0” will determine its future trajectory. A strategic shift toward quality, sustainability, and high-value biologics is essential to remain globally competitive. With timely reforms, India can evolve from the “Pharmacy of the World” to a leader in next-generation drug innovation.

Drishti Mains Question:  “India’s pharmaceutical sector stands at a crossroads between its strength in generics and the need for innovation-driven growth. Examine the key challenges it faces and suggest measures to transform it into a global hub for high-value drug development.”

FAQs: